NINE MASTS CAPITAL Ltd
Source: SEC Form 13F · as of Mar 2026NINE MASTS CAPITAL Ltd holds 25 biotech & pharma companies tracked by BioSniper, totaling $6.7M in value as of Mar 2026 (SEC Form 13F).
Companies held
25
Total value held
$6.7M
BioSniper AIPage evidence connected
Prepared research question
What matters most for Apellis Pharmaceuticals, Inc. (APLS)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| APLSApellis Pharmaceuticals, Inc. | 97,478 | $3.9M |
| RVMDREVOLUTION MEDICINES, INC. | 11,010 | $1.1M |
| ABVXAbivax SA | 7,500 | $835K |
| GALTGALECTIN THERAPEUTICS INC | 19,324 | $54K |
| BMEABiomea Fusion, Inc. | 32,472 | $50K |
| OTLKOutlook Therapeutics, Inc. | 232,546 | $48K |
| PRQRProQR Therapeutics N.V. | 29,518 | $48K |
| LCTXLineage Cell Therapeutics, Inc. | 29,194 | $46K |
| FLNAFilana Therapeutics Inc. | 27,107 | $46K |
| INOINOVIO PHARMACEUTICALS, INC. | 26,317 | $46K |
| IVVDInvivyd, Inc. | 34,698 | $45K |
| PGENPRECIGEN, INC. | 11,608 | $45K |
| HRTXHERON THERAPEUTICS, INC. /DE/ | 53,399 | $43K |
| ALXOALX ONCOLOGY HOLDINGS INC | 20,623 | $41K |
| PDSBPDS Biotechnology Corp | 67,507 | $41K |
| PRLDPrelude Therapeutics Inc | 11,699 | $40K |
| OCGNOcugen, Inc. | 21,938 | $40K |
| CHRSCoherus Oncology, Inc. | 23,018 | $39K |
| JSPRJasper Therapeutics Inc. | 44,165 | $39K |
| BDTXBlack Diamond Therapeutics, Inc. | 17,806 | $38K |
| CCCCC4 Therapeutics, Inc. | 14,157 | $37K |
| ALTAltimmune, Inc. | 11,850 | $36K |
| ATNMActinium Pharmaceuticals, Inc. | 35,227 | $35K |
| HUMAHumacyte Inc. | 54,535 | $33K |
| SGMOQSANGAMO THERAPEUTICS, INC | 113,465 | $28K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.